We are live on ! Find out more
NVS icon

Novartis

1,146 hedge funds and large institutions have $18.5B invested in Novartis in 2021 Q4 according to their latest regulatory filings, with 157 funds opening new positions, 327 increasing their positions, 473 reducing their positions, and 75 closing their positions.

New
Increased
Maintained
Reduced
Closed

148% more call options, than puts

Call options by funds: $688M | Put options by funds: $278M

109% more first-time investments, than exits

New positions opened: 157 | Existing positions closed: 75

6% more funds holding

Funds holding: 1,0801,146 (+66)

3% more capital invested

Capital invested by funds: $18B → $18.5B (+$497M)

0.35% less ownership

Funds ownership: 9.03%8.68% (-0.35%)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

31% less repeat investments, than reductions

Existing positions increased: 327 | Existing positions reduced: 473

Holders
1,146
Holders Change
+66
Holders Change %
+6.11%
% of All Funds
17.64%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
157
Increased
327
Reduced
473
Closed
75
Calls
$688M
Puts
$278M
Net Calls
+$410M
Net Calls Change
+$69.5M
Name Holding Trade Value Shares
Change
Change in
Stake
Mirae Asset Global Investments
126
Mirae Asset Global Investments
South Korea
$12.5M -$337K -4,060 -3%
CSS
127
Cubist Systematic Strategies
Connecticut
$12.2M +$10.8M +129,992 +1,322%
Parallax Volatility Advisers
128
Parallax Volatility Advisers
California
$12.2M +$11.2M +135,356 +3,718%
GIA
129
Guyasuta Investment Advisors
Pennsylvania
$12.1M -$107K -1,291 -0.9%
TCM
130
Tekla Capital Management
Massachusetts
$11.9M
American Century Companies
131
American Century Companies
Missouri
$11.8M -$328K -3,956 -3%
WIC
132
Wilkins Investment Counsel
Massachusetts
$11.6M +$183K +2,200 +2%
BG
133
Bahl & Gaynor
Ohio
$11.5M -$631K -7,603 -5%
RCYC
134
Richard C. Young & Co
Rhode Island
$11.5M -$416K -5,016 -4%
RMCM
135
Reynders McVeigh Capital Management
Massachusetts
$11.3M +$21.9K +264 +0.2%
GD
136
Grandfield & Dodd
New York
$11.3M +$327K +3,940 +3%
Balyasny Asset Management
137
Balyasny Asset Management
Illinois
$11.3M +$10.7M +129,088 New
Osaic Holdings
138
Osaic Holdings
Arizona
$10.9M +$543K +6,536 +6%
Allianz Asset Management
139
Allianz Asset Management
Germany
$10.6M -$76K -915 -0.8%
TBA
140
Tower Bridge Advisors
Pennsylvania
$10.4M -$1.49M -17,984 -13%
Simplex Trading
141
Simplex Trading
Illinois
$10.3M +$9.41M +113,384 +2,534%
CSIC
142
Clifford Swan Investment Counsel
California
$9.76M -$31.1K -374 -0.3%
TBC
143
Tweedy, Browne Co
Connecticut
$9.28M -$423K -5,091 -5%
FWIA
144
Fort Washington Investment Advisors
Ohio
$9.02M -$428K -5,159 -5%
GG
145
Greenwood Gearhart
Arkansas
$8.96M +$722K +8,697 +9%
EHC
146
Everett Harris & Co
California
$8.95M -$10.8M -130,665 -56%
EPAM
147
Euro Pacific Asset Management
Puerto Rico
$8.94M +$899K +10,830 +12%
OA
148
Oxbow Advisors
Texas
$8.86M -$123K -1,479 -1%
William Blair & Company
149
William Blair & Company
Illinois
$8.84M +$856K +10,304 +11%
EVM
150
Evelyn V. Moreno
$8.82M +$801K +9,651 +11%

NVS Hedge Fund Activity: Q4 2021 in Review

1,146 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2021, worth a combined $18.5B — up 2.8% from $18B a quarter earlier.

Buyers outnumbered sellers: 157 funds opened new NVS positions and 75 closed out — a net gain of 82 holders — while 327 added to existing stakes and 473 trimmed.

The largest buyer was Franklin Resources, adding an estimated $196M. The largest seller was Aristotle Capital Management, cutting an estimated $628M.

  • 1,146 institutional investors held Novartis (NVS) as of Q4 2021, up from 1,080 in Q3 2021.
  • Funds reported $18.5B of Novartis stock for Q4 2021, up 2.8% quarter-over-quarter.
  • 157 funds opened new Novartis positions in Q4 2021 and 75 closed out, a net change of +82 holders.
  • The largest Novartis buyer in Q4 2021 was Franklin Resources, an estimated $196M added.
  • The largest Novartis seller in Q4 2021 was Aristotle Capital Management, an estimated $628M sold.

Based on aggregated 13F filings for Q4 2021.